Nurix Therapeutics (NRIX) Projected to Post Quarterly Earnings on Wednesday

Nurix Therapeutics (NASDAQ:NRIX) is anticipated to post its quarterly earnings results before the market opens on Wednesday, April 9th. Analysts expect Nurix Therapeutics to post earnings of ($0.72) per share and revenue of $12.78 million for the quarter.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings results on Tuesday, January 28th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. On average, analysts expect Nurix Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Nurix Therapeutics Price Performance

NASDAQ NRIX opened at $9.72 on Tuesday. The company has a market cap of $741.01 million, a P/E ratio of -3.36 and a beta of 2.23. Nurix Therapeutics has a 12 month low of $8.60 and a 12 month high of $29.56. The company has a 50-day moving average of $15.25 and a 200-day moving average of $19.75.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on NRIX shares. Leerink Partnrs raised shares of Nurix Therapeutics to a “hold” rating in a research note on Monday, March 17th. HC Wainwright reiterated a “buy” rating and issued a $36.00 target price on shares of Nurix Therapeutics in a report on Wednesday, April 2nd. Needham & Company LLC lowered their price target on Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating for the company in a research report on Wednesday, January 29th. JPMorgan Chase & Co. cut their price objective on Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Finally, Royal Bank of Canada boosted their target price on Nurix Therapeutics from $26.00 to $27.00 and gave the stock an “outperform” rating in a report on Wednesday, January 29th. Three analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat, Nurix Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $30.88.

Insider Activity at Nurix Therapeutics

In other news, insider Gwenn Hansen sold 3,690 shares of the stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $73,246.50. Following the completion of the transaction, the insider now directly owns 55,937 shares in the company, valued at approximately $1,110,349.45. This represents a 6.19 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Houte Hans Van sold 2,811 shares of Nurix Therapeutics stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $55,798.35. Following the completion of the sale, the chief financial officer now owns 39,549 shares of the company’s stock, valued at approximately $785,047.65. This trade represents a 6.64 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 12,326 shares of company stock valued at $213,449. Corporate insiders own 7.20% of the company’s stock.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.